Results 171 to 180 of about 20,867 (266)

Micronutrient Deficiencies in the Era of Second-Generation Incretin-Based Therapies for Obesity. [PDF]

Nutrients
Koceva A, Janež A, Pečko T, Jensterle M.   +3 more
europepmc   +1 more source

Tirzepatide‐Induced Functional Small Bowel Obstruction in a Surgically Naïve Patient: A Case Report

Clinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Tirzepatide dose escalation may precipitate functional small bowel obstruction that mimics mechanical obstruction, even in surgically naïve patients. Careful medication review and objective tools such as the water‐soluble contrast challenge can support safe non‐operative management and help avoid unnecessary surgical intervention.
Takuto Shimada, Yoshihiro Nose, Hiroki Tojima, Takahiro Maehata, Akitoshi Kato   +4 more
wiley   +1 more source

Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting. [PDF]

Diabetes Obes Metab
Nauck MA, Punov V, Kang YM, Lim S.
europepmc   +1 more source

The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 5, July 2026.
ABSTRACT Aims The use of pharmacotherapies with weight loss properties for the management of obesity and chronic disease are now routinely prescribed. We investigated the evidence from randomised‐controlled trials for the effects on lean body mass of glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) and sodium‐glucose co‐transporter‐2 inhibitors ...
Rishi Jobanputra, Jack A. Sargeant, Tatiana Plekhanova, Emily James, Abdullah Almaqhawi, David R. Webb, Melanie J. Davies, Thomas Yates   +7 more
wiley   +1 more source

Incretin Mimetics in Cancer and Cardiovascular Disease: JACC: CardioOncology State-of-the-Art Review. [PDF]

JACC CardioOncol
Leong D, Gong S, Sattar N, Narayan V, Reizine NM, Gerstein H, Vellky J.   +6 more
europepmc   +1 more source

Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.
Tirzepatide 15 mg and cagrilintide–semaglutide (CagriSema) achieve the greatest percent body weight reduction (−17.97% and −17.46%, respectively) and the highest rates of ≥ 20% weight loss versus placebo in this network meta‐analysis of 25 randomized trials.
Sultan Hamarsheh, Abdel Rahman Jaber, Omar Abu‐Khazneh, Celina R. Andonie, Saleem Majadleh, Anwar Zahran, Hazem Ayesh   +6 more
wiley   +1 more source

Incretin-Based Therapy and Thyroid Cancer Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

AACE Endocrinol Diabetes
Eisa N, Barood O.
europepmc   +1 more source

Serum Advanced Glycation End Products as Drivers of Poor Tendon Outcomes in Diabetes? An Emerging Hypothesis and Narrative Review

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.
Tendon injuries in diabetes heal poorly, with unclear drivers of extracellular matrix disruption and altered mechanics. This narrative review synthesizes in vitro, animal, and human studies, highlighting serum advanced glycation end products as potential systemic contributors.
Eric J. Gutierrez, Lauren E. Mitevski, Jacob M. Haus, Chad C. Carroll   +3 more
wiley   +1 more source

Role of Evogliptin for Intra‐Class Therapeutic Interchange in Patients With Type 2 Diabetes Mellitus: Subgroup Analysis From A Multi‐Center, Prospective, Observational Study (REVISE Study)

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.
ICTI to evogliptin from other DPP‐4 inhibitors significantly improved glycemic control in patients with type 2 diabetes inadequately controlled on metformin‐based therapy. The treatment was well tolerated, supporting ICTI as a pragmatic optimization strategy in routine clinical practice. ABSTRACT Aims While dipeptidyl peptidase‐4 (DPP‐4) inhibitors are
Jie‐Eun Lee, Jun Hwa Hong, Sung Hoon Yu, Ki‐Hyun Baek, JaeMyung Yu, Seung Jin Lee, Hyung‐Wook Kim, Kang Seo Park, Jung Han Kim, KyungWan Min, Yong Hwan Lee, Koon Soon Kim, Min Soo Song, Ji Hoon Kim, Jong Chul Won   +14 more
wiley   +1 more source

Long-Term Outcomes of Metabolic and Bariatric Surgery: Durability of Weight Loss, Metabolic Remission, and the Changing Treatment Landscape. [PDF]

J Metab Bariatr Surg
Kim Y, Kim KH, Lee SH, Moon Y, Oh Y, Seo KW.   +5 more
europepmc   +1 more source